Entering text into the input field will update the search result below

Hepatitis Test Solution Market Worth $3.37 Billion By 2023

May 18, 2021 8:34 AM ET
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.


  • High burden of hepatitis.
  • Increasing blood transfusion and donations.
  • Benefits of PoC instruments & kits.
  • Awareness initiatives.

Research Methodology:

Top-down and bottom-up approaches were used to validate the size of the global Hepatitis Test Solution Market and estimate the size of various other dependent submarkets. Major players in the market were identified through secondary research, and their market revenues were determined through primary and secondary research.

Secondary sources include annual reports, press releases, and investor presentations of companies; white papers; medical journals; certified publications; articles from recognized authors; gold standard and silver standard websites; directories; and databases. In-depth interviews were conducted with various primary respondents, such as key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as to assess future prospects.

This data is consolidated and added to detailed inputs and analysis from MarketsandMarkets and presented in this report. Some of the secondary resources referred to are World Health Organization (WHO), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), US FDA, Parenteral Drug Association (PDA), International Society for Pharmaceutical Engineering (ISPE), and Washington Biotechnology & Biomedical Association (OTC:WBBA)

Target Audience:

# Blood banks

# Pathologists and pathology laboratories

# Distributors of IVD products

# Research institutes

# Hospitals and clinics

# Healthcare institutions

# Group purchasing organizations (GPOs)

# Market research and consulting firms

Download PDF Brochure@ Download PDF Brochure - Hepatitis Test Solution Market by Technology, Disease Type & End User 2023 | MarketsandMarkets

What the Market Looks Like?

The global hepatitis test solution/diagnosis market is expected to reach USD 3.37 billion by 2023 from USD 2.66 billion in 2018, at a CAGR of 4.9% during the forecast period (2018–2023).

Geographical Growth Scenario:

North America is expected to dominate the hepatitis test solution/diagnosis market in 2018

North America is expected to account for the largest share of the global hepatitis test solution/diagnosis market in 2018. The large share of the North America region is primarily attributed to factors such as the rising adoption of advanced technologies, developed healthcare systems in the US and Canada, and the presence of a large number of leading national clinical laboratories.

The APAC region is expected to grow at the highest CAGR over the next five years. The growth of the hepatitis test solution/diagnosis market in this region is driven by the modernization of healthcare infrastructure, high burden of hepatitis infections, increased healthcare spending by a larger population base, and the rising penetration of cutting-edge clinical laboratory technologies.

Key Players:

The key players operating in this market include Abbott Laboratories (US), Roche (Switzerland), Bio-Rad (US), Siemens (Germany), DiaSorin (OTCPK:ITALY), QIAGEN (Netherlands), bioMérieux (France), Danaher (US), and Grifols (Spain).

Request Sample Pages@ Sample Request - Hepatitis Test Solution Market by Technology, Disease Type & End User 2023 | MarketsandMarkets

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.